Mackenzie Financial Corp Boosts Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Mackenzie Financial Corp boosted its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 4.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,169,176 shares of the company’s stock after buying an additional 238,335 shares during the quarter. Mackenzie Financial Corp owned approximately 2.06% of Maravai LifeSciences worth $33,858,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its stake in shares of Maravai LifeSciences by 163.8% during the third quarter. Glenmede Trust Co. NA now owns 1,108,554 shares of the company’s stock worth $11,086,000 after buying an additional 688,403 shares during the period. Hudson Bay Capital Management LP boosted its stake in shares of Maravai LifeSciences by 171.9% during the third quarter. Hudson Bay Capital Management LP now owns 659,397 shares of the company’s stock worth $6,594,000 after buying an additional 416,876 shares during the period. Mesirow Institutional Investment Management Inc. boosted its stake in shares of Maravai LifeSciences by 33.6% during the third quarter. Mesirow Institutional Investment Management Inc. now owns 926,277 shares of the company’s stock worth $9,263,000 after buying an additional 232,901 shares during the period. Kennedy Capital Management LLC acquired a new stake in shares of Maravai LifeSciences during the third quarter worth about $1,047,000. Finally, Seven Eight Capital LP acquired a new stake in shares of Maravai LifeSciences during the third quarter worth about $172,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Analyst Ratings Changes

MRVI has been the subject of a number of recent analyst reports. Royal Bank of Canada raised their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. Stifel Nicolaus reduced their price objective on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Finally, Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.56.

Maravai LifeSciences Stock Down 5.0 %

Shares of MRVI opened at $7.73 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 8.00 and a quick ratio of 7.41. Maravai LifeSciences Holdings, Inc. has a 1-year low of $4.52 and a 1-year high of $16.62. The firm has a 50 day simple moving average of $7.48 and a 200-day simple moving average of $6.76.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. Analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.